Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karin Mengele

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Biomarkers in Medicine|August 13, 2010
Emerging biomarkers in breast cancer careRudolf Napieralski, Nils Brünner, Karin Mengele, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|December 1, 2009
The effect of antibacterial acting extracorporeal shockwaves on bacterial cell integrityCarsten Horn, Karin Mengele, Ludger Gerdesmeyer, et al.
Oncology Reports|March 29, 2007
Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cellsLisa D Sprague, Herbert Tomaso, Karin Mengele, et al.
Anti-Cancer Drugs|August 12, 2008
Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case reportHans-Joachim Stemmler, Karin Mengele, Manfred Schmitt, et al.
International Journal of Molecular Medicine|September 25, 2008
Expression of metalloprotease insulin-degrading enzyme insulysin in normal and malignant human tissuesChristina Yfanti, Karin Mengele, Apostolos Gkazepis, et al.
Molecular Cancer Research : MCR|February 1, 2013
Effects of simultaneous knockdown of HER2 and PTK6 on malignancy and tumor progression in human breast cancer cellsNatalie Ludyga, Natasa Anastasov, Michael Rosemann, et al.
Expert Review of Molecular Diagnostics|November 18, 2010
Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1Manfred Schmitt, Karin Mengele, Rudolf Napieralski, et al.
Expert Review of Molecular Diagnostics|October 23, 2010
Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1Karin Mengele, Rudolf Napieralski, Viktor Magdolen, et al.
BMC Cancer|August 1, 2007
Induction of plasminogen activator inhibitor type-1 (PAI-1) by hypoxia and irradiation in human head and neck carcinoma cell linesDaniela Schilling, Christine Bayer, Anneke Geurts-Moespot, et al.
International Journal of Molecular Medicine|August 4, 2005
Ex vivo detection of apoptotic trophoblast cells applying flow cytofluorometry and immunocytochemistry using M30 antibody directed to the cytokeratin 18 neo-epitopeJanna Krol, Karin Mengele, Irina Ottl-Mantchenko, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Biomarkers in Medicine|August 13, 2010
Emerging biomarkers in breast cancer careRudolf Napieralski, Nils Brünner, Karin Mengele, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|December 1, 2009
The effect of antibacterial acting extracorporeal shockwaves on bacterial cell integrityCarsten Horn, Karin Mengele, Ludger Gerdesmeyer, et al.
Oncology Reports|March 29, 2007
Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cellsLisa D Sprague, Herbert Tomaso, Karin Mengele, et al.
Anti-Cancer Drugs|August 12, 2008
Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case reportHans-Joachim Stemmler, Karin Mengele, Manfred Schmitt, et al.
International Journal of Molecular Medicine|September 25, 2008
Expression of metalloprotease insulin-degrading enzyme insulysin in normal and malignant human tissuesChristina Yfanti, Karin Mengele, Apostolos Gkazepis, et al.
Molecular Cancer Research : MCR|February 1, 2013
Effects of simultaneous knockdown of HER2 and PTK6 on malignancy and tumor progression in human breast cancer cellsNatalie Ludyga, Natasa Anastasov, Michael Rosemann, et al.
Expert Review of Molecular Diagnostics|November 18, 2010
Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1Manfred Schmitt, Karin Mengele, Rudolf Napieralski, et al.
Expert Review of Molecular Diagnostics|October 23, 2010
Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1Karin Mengele, Rudolf Napieralski, Viktor Magdolen, et al.
BMC Cancer|August 1, 2007
Induction of plasminogen activator inhibitor type-1 (PAI-1) by hypoxia and irradiation in human head and neck carcinoma cell linesDaniela Schilling, Christine Bayer, Anneke Geurts-Moespot, et al.
International Journal of Molecular Medicine|August 4, 2005
Ex vivo detection of apoptotic trophoblast cells applying flow cytofluorometry and immunocytochemistry using M30 antibody directed to the cytokeratin 18 neo-epitopeJanna Krol, Karin Mengele, Irina Ottl-Mantchenko, et al.
Pageof 2